CEO Johan Wäborg at Redeye Investor Forum

At April 10 Johan Wäborg, CEO at Iconovo presented the company at Redeye Investor Forum in Gothenburg, Sweden. Iconovo: CEO Johan Wäborg presents…

CEO Johan Wäborg: how do we take GLP-1’s in the future?

Why would you inject yourself… if you could just sniff it? No one likes needles. It becomes a big deal when you’re talking about the world’s most…

Iconovo at Carnegie småbolagsdag

Want to learn more about Iconovo? Listen to Johan Wäborg, CEO at Iconovo presenting the company at Carnegie's småbolagsdag. It's streamed live at 11:05…

Redeye: Iconovo company presentation

Johan Wäborg, CEO of Iconovo, presented what's going on at Iconovo at the Redeye Theme: Medtech & Diagnostics Event 2024. What's going on? Please…

BIOSTOCK: Inhalationsspecialisterna Iconovo tar in kapital (Swedish only)

En intranasal fetmabehandling under utveckling, en generisk utmanare till astmaprodukten Symbicort och samtal med potentiella partners står på agendan…

Iconovo’s partner Amneal has taken the next important step in the clinical development of ICOres budesonide/formoterol

Iconovo announces that the company's development partner Amneal Pharmaceuticals has completed a clinical pharmacokinetic pilot study comparing ICOres budesonide/formoterol…

Iconovo receives positive guidance from FDA regarding substitutability for ICOpre

Iconovo announces that the US Food and Drug Administration (FDA) has issued a positive guidance regarding the generic substitutability of the company's…

BIOSTOCK: The future of obesity treatment – Iconovo develops intranasal semaglutide

This morning, BIOSTOCK released an article regarding Iconovo's development of an intranasal semaglutide formulation for the treatment of obesity in the…

Iconovo develops intranasally inhaled semaglutide in ICOone Nasal for more user-friendly treatment of overweight and obesity

Iconovo announced today that the company has initiated the development of the GLP-1 analogue semaglutide in the inhaler ICOone Nasal for intranasal treatment…

Systemic Delivery of Biologics via Inhalation: Overcoming Injection Aversion in Modern Therapies

That was the title of the talk by Dr Orest Lastow, CTO at Iconovo, at the meeting New updates in Drug Formulation & Bioavailability organized by Life Science…